Blackstone and TPG are looking to sell a division of Hologic for more than $4 billion, according to reports. This move is part of their strategy to realize value from the $18.3 billion acquisition of Hologic, a medical technology company. The original acquisition saw Blackstone and TPG advising Hologic with Goldman Sachs and Wachtell Lipton Rosen & Katz, while Blackstone was advised by Citigroup, Kirkland & Ellis, and Ropes & Gray.
The sale of a Hologic unit would allow the private equity firms to generate cash from their substantial investment. Hologic specializes in various medical technologies, and the divestment signals a strategic optimization of the acquired assets. The deal highlights a trend of private equity firms actively managing portfolios to maximize returns.
This transaction occurs in a dynamic healthcare M&A landscape. Diagnostics manufacturers, including Hologic, were prominent during the COVID-19 pandemic due to their pivotal role in testing. The industry has seen significant deal activity, with diagnoses acquisitions flourishing. Firms like TPG have been active in the sector, leveraging market shifts and a strong demand for healthcare technologies.
Citigroup, which advised Blackstone on the Hologic acquisition, has been noted for its strong presence in healthcare M&A deals, indicating its continued involvement in significant transactions within the sector. The proposed sale underscores the financial maneuvering and strategic divestitures common in large-scale private equity transactions.
